Next-Gen Modality Convergence: ADCs, Radiopharmaceuticals, Bispecifics, and Protein Degraders
Wed, May 13
|
04:20 PM - 05:00 PM
Session details:
The strongest pipelines in 2026 are being built around new ways to reach previously 'undruggable' targets and deliver payloads precisely. This panel maps where the field is converging and what it means for development strategy, endpoints, and manufacturing.
Key discussion points:
• ADCs: next-generation linkers, novel payloads, and expansion beyond classic oncology
• Radiopharmaceuticals: development, reimbursement signals, and isotope supply constraints
• Multispecific antibodies and complex formats: differentiation and developability
• Targeted protein degradation: molecular glues and post-PROTAC advances moving into the clinic
